Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company experienced a 9.16% year-on-year decline in total revenue for H1 2025, amounting to $278 million, primarily due to intensified domestic market competition and adjustments in the sales team and marketing strategy [6] - The core product, Furmonertinib, continues to show strong growth in overseas markets, with sales increasing by 25% year-on-year to $163 million [6] - The company has adjusted its net profit forecasts for 2025-2027 to $236.7 million, $50.1 million, and $68.2 million respectively, with corresponding EPS of $2.7, $0.6, and $0.8 [6] - The company maintains a strong competitive position with several core products and is set to submit an IND application for its ATTC product by the end of 2025 [6][8] Financial Summary and Valuation Metrics - Total revenue projections for 2025 are $427.4 million, with a year-on-year decline of 5.5% [10] - The net profit for 2025 is projected at $236.7 million, reflecting a significant increase of 774.2% compared to 2024 [10] - The company’s gross margin is expected to be 39% in 2025, with a net margin of 58.3% [10] - The current P/E ratios for 2025, 2026, and 2027 are projected at 8.1, 38.1, and 28.0 respectively [10] Product Development and Clinical Progress - The FRUSICA-2 Phase III study for Furmonertinib in combination with Dabrafinib for renal cell carcinoma has yielded positive results, with the new drug application accepted by CDE in June 2025 [7] - The company’s first hematological oncology drug, Tazemetostat, has been commercialized in mainland China [7] - The ATTC platform, a new generation of antibody-drug conjugates, is expected to initiate clinical trials by the end of 2025, with additional candidates planned for IND submission in 2026 [8]

Core Viewpoint - CICC has downgraded the revenue forecast for Hutchison China MediTech (00013) for 2025 by 12.4% to $594 million, and the net profit forecast for 2026 by 65% to $35 million, while maintaining the 2025 net profit forecast at $366 million due to the timing of equity sale gains. The target price remains at HKD 30, indicating a potential upside of 24.7% from the current stock price [1]. Group 1 - The company's 1H25 performance was below expectations, with revenue of $278 million, down 9% year-on-year, primarily due to lower domestic product sales. The net profit attributable to shareholders was $455 million, mainly due to gains from the sale of non-core business equity. The comprehensive revenue from the oncology immunotherapy business in 1H25 was $144 million, down 15% year-on-year, leading to a downward revision of the full-year revenue guidance from $350-450 million to $270-350 million [2]. Group 2 - The overseas sales of furmonertinib reached $163 million in 1H25, up 25% year-on-year, showing steady growth. The drug has been approved for sale in over 30 countries and regions, expanding insurance reimbursement coverage and increasing market share. However, domestic sales of furmonertinib, savolitinib, and surufatinib declined year-on-year due to sales structure adjustments and changes in the competitive landscape. The company expects improved sales trends in the second half of the year due to new indications for savolitinib and successful overseas sales of furmonertinib [3]. Group 3 - The antibody-drug conjugate (ATTC) candidate HMPL-A251 is expected to enter clinical trials in the second half of 2025, having shown good proof of concept in preclinical models. The company plans to initiate Phase 1 clinical studies in China and the U.S. in 2H25, with two other candidates, HMPL-A580 and HMPL-A830, set to start Phase 1 clinical studies in 2026. Attention is recommended for the clinical validation of this next-generation technology platform [4]. Group 4 - The company anticipates completing the enrollment for savolitinib SAFFRON in 2H25, with data readout expected in 1H26. The SANOVO enrollment is also expected to be completed in 2H25. The application for the re-submission of surufatinib in China is planned for 1H26, and the data for surufatinib in first-line pancreatic ductal adenocarcinoma is expected to be read out in 2H25 [5].

Core Viewpoint - CICC has downgraded the revenue forecast for Hutchison China MediTech (00013) for 2025 by 12.4% to $594 million, and the net profit forecast for 2026 by 65% to $35 million, while maintaining the 2025 net profit forecast at $366 million due to the timing of equity sale gains. The firm maintains an "outperform" rating, citing progress in the company's innovation pipeline and a target price of HKD 30, indicating a potential upside of 24.7% from the current stock price [1]. Group 1 - The company's 1H25 performance was below expectations, with revenue of $278 million, down 9% year-on-year, primarily due to lower-than-expected domestic product sales. The net profit attributable to shareholders was $455 million, mainly due to gains from the sale of non-core business equity. The company has lowered its full-year guidance for comprehensive revenue from the oncology immunotherapy business from $350-450 million to $270-350 million [2]. - The overseas sales of furmonertinib were strong in 1H25, reaching $163 million, a 25% year-on-year increase. The drug has been approved for sale in over 30 countries and regions, expanding insurance reimbursement coverage and increasing market share. However, domestic sales of furmonertinib, savolitinib, and sugemalimab declined year-on-year due to sales structure adjustments and changes in the competitive landscape. The company expects sales trends to improve in the second half of the year due to new indications for savolitinib and successful overseas sales of furmonertinib [3]. Group 2 - The antibody-drug conjugate (ATTC) candidate HMPL-A251 is expected to enter clinical trials in the second half of 2025, having shown good proof of concept in preclinical models. The company plans to initiate Phase 1 clinical studies in China and the U.S. in 2H25, with two other candidates, HMPL-A580 and HMPL-A830, expected to start Phase 1 clinical studies in 2026. Attention is recommended for the clinical validation of this new generation technology platform [4]. - Other R&D progress includes the completion of savolitinib SAFFRON enrollment in 2H25, with data readout expected in 1H26, and SANOVO enrollment completion in 2H25. The company plans to resubmit the application for the marketing authorization of sugemalimab in China in 1H26, and data for sugemalimab in first-line pancreatic ductal adenocarcinoma is expected in 2H25 [5].

Core Insights - Amgen/Zai Lab announced the success of the Phase III clinical trial for Bemarituzumab, the first and only FGFR2b inhibitor demonstrating overall survival (OS) benefits in first-line treatment for gastric cancer, marking a significant breakthrough in the field [1][13]. Group 1: Development History of Gastric Cancer Drugs - Gastric cancer (GC) is a common and aggressive malignancy with high heterogeneity, ranking third in incidence and mortality among various cancers [1]. - The development of gastric cancer treatments has evolved through four stages: chemotherapy, targeted therapy, immunotherapy, and precision medicine [1][2][5]. - Early chemotherapy relied on 5-FU and platinum-based drugs, which had limitations such as limited efficacy and significant side effects [1]. Group 2: Targeted Therapies and Innovations - The targeted therapy era saw the emergence of several drugs, including Trastuzumab and Ramucirumab, which have changed treatment paradigms for HER2-positive gastric cancer [2][3]. - Despite advancements, targeted therapies face challenges such as limited patient populations and resistance issues [3]. - The immunotherapy era introduced PD-1/PD-L1 inhibitors, significantly impacting treatment options for advanced gastric cancer [5]. Group 3: Emerging Targets and Clinical Trials - Current innovative therapies target multiple biomarkers, including HER2, Claudin18.2, and FGFR2b, with ongoing clinical trials exploring their efficacy [7][12][13]. - The ADC drug targeting HER2, Trastuzumab Deruxtecan, has shown promising results, extending median OS by 3.3 months compared to standard therapies [10]. - Claudin18.2 is emerging as a promising target, with Zolbetuximab recently approved for use in combination with chemotherapy [12]. Group 4: Domestic Market Dynamics - China accounts for approximately 40% of the global gastric cancer cases, creating a significant market opportunity for domestic pharmaceutical companies [15]. - Companies like Hengrui and Rongchang Biopharma are actively developing innovative therapies targeting HER2 and Claudin18.2, with ongoing clinical trials showing encouraging results [16][19]. - The competitive landscape is intensifying as domestic firms explore new targets such as MET and FGFR2b, aiming to address unmet medical needs in gastric cancer treatment [20][21].

Macro Strategy - The report indicates that loan demand is expected to decline in July, while social financing growth is projected to remain stable [1][22] - The ECI supply index is at 50.06%, showing a slight decrease, while the demand index is at 49.90%, indicating a contraction in both supply and demand [22] - The report highlights a potential rebound in CPI due to rising commodity prices, which may affect market expectations for interest rate cuts in September [1][23] Industry Analysis - The report discusses historical capacity adjustment cases, emphasizing that government intervention is more effective than non-intervention in addressing capacity imbalances [2][4] - It notes that supply-demand rebalancing requires simultaneous efforts in controlling capacity, restoring credit, and stabilizing employment [2] - The "反内卷" policy is expected to differ from previous supply-side reforms, focusing on market-driven measures rather than administrative interventions [6][7] Company Insights - For Hehuang Pharmaceutical, the net profit forecast for 2025 has been adjusted to $41.4 million due to asset sales, while future projections have been revised downwards due to delays in product launches [11] - For Dazhong Media, the profit forecast for 2025-2027 has been adjusted, reflecting the impact of the "碰一碰" business model on profit elasticity and cost optimization [12] - For Di'er Laser, the company reported a 29.2% year-on-year revenue growth in H1 2025, driven by strong performance in the photovoltaic equipment sector [13][14]

Group 1: Guanggang Gas (688548.SH) - The company's Q2 2025 profitability has rebounded sequentially, with revenue of 5.66 billion yuan, a year-on-year increase of 10.60% and a quarter-on-quarter increase of 3.24% [6] - The company reported a H1 2025 revenue of 11.14 billion yuan, a year-on-year increase of 14.56%, but a net profit of 1.03 billion yuan, a year-on-year decrease of 21.14% [6][7] - The company is expected to achieve net profits of 256 million, 410 million, and 589 million yuan for 2025-2027, corresponding to PE ratios of 52.4, 32.7, and 22.7 times, respectively [8] Group 2: Hutchison China MediTech (0013.HK) - The company reported H1 2025 revenue of 277.7 million USD, a decrease of 9%, with the oncology/immunology business declining by 15% [10][11] - The updated revenue forecast for 2025-2027 is 605 million, 652 million, and 721 million USD, with year-on-year growth rates of -4.0%, 7.7%, and 10.7% [12] - The company has a strong cash position of 1.3645 billion USD, which supports the development of its ATTC platform, expected to contribute to revenue growth [12] Group 3: Boyuan Chemical (000683.SZ) - The company reported H1 2025 revenue of 5.916 billion yuan, a year-on-year decrease of 16.31%, and a net profit of 743 million yuan, a decrease of 38.57% [14][15] - The company expects net profits of 1.48 billion, 2.006 billion, and 2.33 billion yuan for 2025-2027, with corresponding PE ratios of 14.6, 10.7, and 9.3 times [16] - The Alashan natural soda project is progressing, with plans for completion by the end of 2025, which is expected to enhance production capacity [16]

Investment Rating - The report maintains a "Buy" rating for the company [1][7][13] Core Insights - The company recently received approval for a new indication of Savolitinib, which will expand its treatment options for lung cancer patients [6] - The ATTC pipeline is set to enter clinical development, with the first candidate expected to begin trials by the end of 2025 [6] - The company's revenue for the first half of 2025 was $278 million, a year-on-year decrease of 9.16%, primarily due to increased competition in the Chinese market [4][5] Financial Performance - The company reported a net profit of $455 million for the first half of 2025, benefiting from the sale of a 45% stake in Shanghai Hutchison Pharmaceuticals, which generated $416 million in after-tax proceeds [4] - The revenue forecast for 2025, 2026, and 2027 is $610 million, $695 million, and $771 million respectively, with expected growth rates of -3.22%, 13.88%, and 11.07% [7][9] - The projected net profit for the same years is $419 million, $113 million, and $136 million, with growth rates of 1,011.38%, -73.01%, and 20.58% respectively [7][9] Product Performance - Domestic sales of Furmonertinib (爱优特®) decreased by 29.51% year-on-year to $43 million due to intensified competition [5] - However, overseas sales of Furmonertinib (FRUZAQLA®) increased by 24.75% year-on-year to $163 million, attributed to market expansion into over 30 countries [5] Market Position - The company’s stock has a market capitalization of HKD 210.7 billion, with a 12-month high of HKD 34.8 and a low of HKD 18.36 [3]

Investment Rating - The report assigns a rating of "Accumulate" to the company, which has been downgraded from a previous rating [1]. Core Views - The company's performance in the first half of 2025 was slightly below expectations, but a turnaround is anticipated in the second half of the year [1]. - The total revenue for H1 2025 was reported at $280 million, reflecting a year-on-year decline of 9.2% [7]. - The company has adjusted its revenue guidance for the full year 2025 to between $270 million and $350 million for its oncology/immunology segment [7]. Financial Summary - Total revenue projections for 2023A, 2024A, 2025E, 2026E, and 2027E are $838 million, $630.2 million, $560 million, $635.91 million, and $711.90 million respectively, with year-on-year changes of 96.52%, -24.80%, -11.14%, 13.55%, and 11.95% [1]. - The net profit attributable to the parent company is forecasted to be $100.78 million, $37.73 million, $413.55 million, $14.50 million, and $62.82 million for the same years, with year-on-year changes of 127.93%, -62.56%, 996.09%, -96.49%, and 333.23% [1]. - The latest diluted EPS is projected to be $0.12, $0.04, $0.47, $0.02, and $0.07 for the years 2023A to 2027E [1]. - The P/E ratios for the years 2023A, 2024A, 2025E, 2026E, and 2027E are 26.55, 70.92, 6.47, 184.55, and 42.60 respectively [1]. Key Catalysts - The report highlights several important catalysts for the company, including the potential participation of the drug "Sewotini" in the national medical insurance negotiations by the end of this year [7]. - The global Phase III study for "Sewotini" is expected to read out data in the first half of 2026, with plans to submit for FDA approval [7]. - The company is also working on new drug candidates through its innovative antibody-drug conjugate (ATTC) platform, with plans to enter clinical development by the end of 2025 [7].

Group 1 - Kuaishou (快手) is expected to achieve net profits of 177 billion, 210 billion, and 244 billion yuan in 2025-2027, driven by AI business differentiation and commercialization breakthroughs, receiving a "buy" rating from Western Securities [2] - Hutchison China MediTech (和黄医药) has seen its core product revenues fall below expectations, leading to a downward revision of its annual tumor revenue guidance, but maintains a "buy" rating due to strong cash reserves and potential for external asset acquisition [3] - Hua Hong Semiconductor (华虹半导体) reported better-than-expected gross margins in Q2 2025 and has positive revenue and margin guidance for Q3 2025, supported by stable demand growth and domestic order recovery, receiving an "outperform" rating from CICC [4][5] Group 2 - China General Nuclear Power (中广核电力) has its rating upgraded to "outperform" with a target price of 3.7 HKD, as new sales agreements are expected to have a minimal cost impact, and the outlook for projects is clear [6] - Kingdee International (金蝶国际) reported mid-term results in line with expectations, with AI contract scale exceeding forecasts, leading to adjusted revenue predictions for 2025-2027, maintaining a "buy" rating [7] - Q Technology (丘钛科技) is benefiting from strong IoT demand, with an upward adjustment of the target price to 17.9 HKD, as the momentum is expected to continue driving profit growth into 2026 [8] Group 3 - Conant Optical (康耐特光学) is projected to achieve a compound annual growth rate of 26% in EPS from 2025-2026, supported by its R&D capabilities and customer base, receiving an "outperform" rating [9] - Semiconductor Manufacturing International Corporation (中芯国际) has a neutral rating with a target price adjustment to 47 HKD, as average chip prices are expected to be higher in Q3 compared to Q2, with revenue forecasts for 2025 and 2026 at 9.29 billion and 11 billion USD respectively [10] - Anjoy Foods (安井食品) is recognized as a leader in the frozen food industry in China, with a projected market share of 6.6% in 2024, and is expected to maintain its market position due to operational excellence and product development experience, receiving a "buy" rating [11]

Core Viewpoint - Daiwa has downgraded the revenue forecast for Hutchison China MediTech (00013) for the years 2025 to 2027 by 16% to 29% due to lowered domestic drug sales expectations [1] Revenue Forecast - The new projections for total drug sales are expected to grow by 6%, 21%, and 28% for the years 2025, 2026, and 2027 respectively, compared to previous estimates of 34%, 36%, and 33% [1] - The latest net profit estimates are $433 million, $30 million, and $40 million for the years 2025, 2026, and 2027 respectively [1] Rating and Target Price - Daiwa maintains a "Buy" rating for Hutchison China MediTech, with a target price reduced from HKD 33 to HKD 30 [1] Sales Performance - The company's product sales in the first half of the year decreased by 4% year-on-year to $234 million, primarily due to competitive risks in the domestic market, team restructuring, and industry anti-corruption impacts [1] Drug Development Progress - The progress of Sovleplenib has been delayed, with the company aiming to resubmit its application in the first half of next year [1] - The group plans to advance the development of a new generation Syk inhibitor, with an IND application expected to be submitted in the second quarter of next year [1] Positive Developments - The ATTC platform has achieved breakthroughs, with the first candidate drug HMPL-A251's IND application set to be submitted in early September, and preclinical data to be presented at the EORTC conference [1] - Two additional ATTC drugs are expected to initiate Phase I clinical trials next year [1] Profit Performance - The company reported a net profit of $455 million in the first half of the year, compared to $26 million in the same period last year, mainly due to the sale of part of its non-core joint venture equity, generating $416 million in revenue [1]